Science and Technology

Trump announces new deal with pharma companies to cut drug prices | Health News

United States President Donald Trump announced new agreements aimed at lowering prescription drug prices.

On Friday, alongside leaders from Bristol Myers Squibb, Gilead Sciences, and Merck, among other leading pharma giants, the president announced deals that would cut prices on their medications to match that of the developed nation with the lowest price.

Recommended Stories

list of 4 itemsend of list

“Starting next year, American drug prices will come down fast and furious and will soon be some of the lowest in the developed world,” Trump said.

“This is the biggest thing having to do with drugs in the history of the purchase of drugs.”

Under the deals, each drugmaker will cut prices on some of the drugs sold to the Medicaid programme for low-income people, senior administration officials said, promising “massive savings” on widely used medicines without giving specific figures.

“We were subsidising the entire world. We’re not doing it anymore,” Trump said at a White House news conference, flanked by nine pharma executives.

Mehmet Oz, the director of the Centres for Medicare and Medicaid Service, said Regeneron, Johnson & Johnson, and AbbVie would visit the White House after the holidays for the launch of the government’s TrumpRx website.

US patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.

The details of each deal were not immediately available, but officials said they included agreements to cut cash-pay direct-to-consumer prices of select drugs sold potentially through the TrumpRx.gov website, to launch drugs in the US at prices equal to – not lower than – those in other wealthy nations and to increase manufacturing. In return, companies can receive a three-year exemption from any tariffs.

Drug prices fall

Merck said it will sell its diabetes drugs Januvia, Janumet and Janumet XR – set to face generic competition next year – directly to US consumers at about 70 percent off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels.

Enlicitide is one of two Merck drugs expected to receive a speedy review under the FDA’s new, fast-track pathway, the Reuters news agency has previously reported.

Amgen said it will expand its direct-to-patient programme to include migraine drug Aimovig and rheumatoid arthritis medicine Amjevita, offering both at $299 a month – nearly 60 percent and 80 percent below current US list prices.

In July, Trump sent letters to leaders of 17 major pharmaceutical companies, outlining how they should provide so-called most-favoured -nation prices to the US government’s Medicaid health programme for low-income people, and guarantee that new drugs will not be launched at prices above those in other high-income countries.

So far, five companies have struck deals with the administration to rein in prices. They are Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk and EMD Serono, the US division of Germany’s Merck.

A portion of revenues from each company’s foreign sales will also be remitted to the US to offset costs, officials said.

The companies pledged together to invest more than $150bn in the US for R&D and manufacturing, according to officials, although it was unclear whether that included earlier commitments. Several also agreed to donate drug ingredients to the US strategic reserve.

Trump has long focused on the disparity between drug prices in the US and other wealthy countries, which have government-run health systems that negotiate price discounts.

The spectre of tighter price controls by the US government initially spooked investors, but the terms of the deals announced so far have calmed many of those fears.

Analysts have noted that Medicaid, which accounts for only approximately 10 percent of US drug spending, already benefits from substantial price discounts, exceeding 80 percent in some cases.

Source link

Can India catch up with the US, Taiwan and China in the global chip race? | Technology News

In October, a small electronics manufacturer in the western Indian state of Gujarat shipped its first batch of chip modules to a client in California.

Kaynes Semicon, together with Japanese and Malaysian technology partners, assembled the chips in a new factory funded with incentives under Indian Prime Minister Narendra Modi’s $10bn semiconductor push announced in 2021.

Modi has been trying to position India as an additional manufacturing hub for global companies that may be looking to expand their production beyond China, with limited success.

One sign of that is India’s first commercial foundry for mature chips that is currently under construction, also in Gujarat. The $11bn project is supported by technology transfer from a Taiwanese chipmaker and has onboarded the United States chip giant Intel as a potential customer.

With companies the world over hungering for chips, India’s entry into that business could boost its role in global supply chains. But experts caution that India still has a long way to go in attracting more foreign investment and catching up in cutting-edge technology.

Unprecedented momentum

Semiconductor chips are designed, fabricated in foundries, and then assembled and packaged for commercial use. The US leads in chip design, Taiwan in fabrication, and China, increasingly, in packaging.

The upcoming foundry in Gujarat is a collaboration between India’s Tata Group, one of the largest conglomerates in the country, and Taiwan’s Powerchip Semiconductor Manufacturing Corporation (PSMC), which is assisting with the plant’s construction and technology transfer.

On December 8, Tata Electronics also signed an agreement with Intel to explore the manufacturing and packaging of its products in Tata’s upcoming facilities, including the foundry. The partnership will address the growing domestic demand.

Last year, Tata was approved for a 50 percent subsidy from the Modi government for the foundry, along with additional state-level incentives, and could come online as early as December 2026.

Even if delayed, the project marks a pivotal moment for India, which has seen multiple attempts to build a commercial fab stall in the past.

The foundry will focus on fabricating chips ranging from 28 nanometres (nm) to 110nm, typically referred to as mature chips because they are comparatively easier to produce than smaller 7nm or 3nm chips.

Mature chips are used in most consumer and power electronics, while the smaller chips are in high demand for AI data centres and high-performance computing. Globally, the technology for mature chips is more widely available and distributed. Taiwan leads production of these chips, with China fast catching up, though Taiwan’s TSMC dominates production for cutting-edge nodes below 7nm.

“India has long been strong in chip design, but the challenge has been converting that strength into semiconductor manufacturing,” said Stephen Ezell, vice president for global innovation policy at the Washington, DC-based Information Technology and Innovation Foundation (ITIF).

“In the past two to three years, there’s been more progress on that front than in the previous decade – driven by stronger political will at both the central and state levels, and a more coordinated push from the private sector to commit to these investments,” Ezell told Al Jazeera.

Easy entry point

More than half of the Modi government’s $10bn in semiconductor incentives is earmarked for the Tata-PSMC venture, with the remainder supporting nine other projects focused mainly on the assembly, testing and packaging (ATP) stage of the supply chain.

These are India’s first such projects – one by Idaho-based Micron Technology, also in Gujarat, and another by the Tata Group in the northeastern Assam state. Both will use in-house technologies and have drawn investments of $2.7bn and $3.3bn, respectively.

The remaining projects are smaller, with cumulative investments of about $2bn, and are backed by technology partners such as Taiwan’s Foxconn, Japan’s Renesas Electronics, and Thailand’s Stars Microelectronics.

“ATP units offer a lower path of resistance compared to a large foundry, requiring smaller investments – typically between $50m and $1bn. They also carry less risk, and the necessary technology know-how is widely available globally,” Ashok Chandak, president of the India Electronics and Semiconductor Association (IESA), told Al Jazeera.

Still, most of the projects are behind schedule.

Micron’s facility, approved for incentives in June 2023, was initially expected to begin production by late 2024. However, the company noted in its fiscal 2025 report that the Gujarat facility will “address demand in the latter half of this decade”.

Approved in February 2024, the Tata facility was initially slated to be operational by mid-2025, but the timeline has now been pushed to April 2026.

When asked for reasons behind the delays, both Micron and Tata declined to comment.

One exception is a smaller ATP unit by Kaynes Semicon, which in October exported a consignment of sample chip modules to an anchor client in California – a first for India.

Another project by CG Semi, part of India’s Murugappa Group, is in trial runs, with commercial production expected in the coming months.

The semiconductor projects under the Tata Group and the Murugappa Group have drawn public scrutiny after Indian online news outlet Scroll.in reported that both companies made massive political donations after they were picked for the projects.

As per Scroll.in, the Tata Group donated 7.5 billion rupees ($91m) and 1.25 billion rupees ($15m), respectively, to Modi’s Bharatiya Janata Party (BJP) just weeks after securing government subsidies in February 2024 and ahead of national elections. Neither group had made such large donations to the party before. Such donations are not prohibited by law. Both the Tata Group and the Murugappa Group declined to comment to Al Jazeera regarding the reports.

Meeting domestic demand a key priority

The upcoming projects in India – both the foundry and the ATP units – will primarily focus on legacy, or mature, chips sized between 28nm and 110nm. While these chips are not at the cutting-edge of semiconductor technology, they account for the bulk of global demand, with applications across cars, industrial equipment and consumer electronics.

China dominates the ATP segment globally with a 30 percent share and accounted for 42 percent of semiconductor equipment spending in 2024, according to DBS Group Research.

India has long positioned itself as a “China Plus One” destination amid global supply chain diversification, with some progress evident in Apple’s expansion of its manufacturing base in the country. The company assembles all its latest iPhone models in India, in partnership with Foxconn and Tata Electronics, and has emerged as a key supplier to the US market this year following tariff-related uncertainties over Chinese shipments.

Its push in the ATP segment, however, is driven largely by the need to meet the growing domestic demand for chips, anticipated to surge from $50bn today to $100bn by 2030.

“Globally, too, the market will expand from around $650bn to $1 trillion. So, we’re not looking at shifting manufacturing from China to elsewhere. We’re looking at capturing the incremental demand emerging both in India and abroad,” Chandak said.

India’s import of chips – both integrated circuits and microassemblies – has jumped in recent years, rising 36 percent in 2024 to nearly $24bn from the previous year. An integrated circuit (IC) is a chip serving logic, memory or processing functions, whereas a microassembly is a broader package of multiple chips performing combined functions.

The momentum has continued this year, with imports up 20 percent year-on-year, accounting for about 3 percent of India’s total import bill, according to official trade data. China remains the leading supplier with a 30 percent share, followed by Hong Kong (19 percent), South Korea (11 percent), Taiwan (10 percent), and Singapore (10 percent).

“Even if it’s a 28 nm chip, from a trade balance perspective, India would rather produce and package it domestically than import it,” Ezell of ITIF said, adding that domestic capability would enhance the competitiveness of chip-dependent industries.

Better incentives needed

The Modi government’s support for the chip sector, while unprecedented for India, is still dwarfed by the $48bn committed by China and the $53bn provisioned under the US’s CHIPS Act.

To achieve scale in the ATP segment for meaningful import substitution – and to advance towards producing chips smaller than 28nm – India will need continued government support, and there is a second round of incentives already in the works.

“The reality is, if India wants to compete at the leading edge of semiconductors, it will need to attract a foreign partner – American or Asian – since only a handful of companies globally operate at that level. It’s highly unlikely that a domestic firm will be competitive at 7nm or 3nm anytime soon,” Ezell said.

According to him, India needs to continue focusing on improving its overall business environment – from ensuring reliable power and infrastructure to streamlining regulations, customs and tariff policies.

India’s engineers make up about a fifth of the global chip design workforce, but rising competition from China and Malaysia to attract multinational design firms could erode that edge.

In its latest incentive round, the Indian government limited benefits to domestic firms to promote local intellectual property – a move that, according to Alpa Sood, legal director at the India operations of California-based Marvell Technology, risks driving multinational design work elsewhere.

“India already has a thriving chip design ecosystem strengthened by early-stage incentives from the government. What we need, to further accelerate and build stronger R&D muscle – is incentives that mirror competing countries like China [220 percent tax incentives] and Malaysia [200 percent tax incentives]. This will ensure we don’t lose the advantage we’ve built over the years,” Sood told Al Jazeera.

Marvell’s India operations are its largest outside the US.

The Trump effect

India’s upcoming chip facilities, while aimed at meeting domestic demand, will also export to clients in the US, Japan, and Taiwan. Though US President Donald Trump has threatened 100 percent tariffs on semiconductors made outside the US, none have yet been imposed.

A bigger concern for India-US engagement – so far limited to education and training – is Washington’s 50 percent tariff on India over its Russian crude imports. Semiconductors remain exempt, but the broader trade climate has turned uncertain.

“Over half the global semiconductor market is controlled by US-headquartered firms, making engagement with them crucial,” Chandak said. “Any alignment with these firms, either through joint ventures or technology partnerships – is a preferred option.”

The global chip race is accelerating, and India’s policies will need to keep pace to become a serious player amid growing geo-economic fragmentation.

“These new 1.7nm fabs are so advanced they even factor in the moon’s gravitational pull – it’s literally a moonshot,” Ezell said. “Semiconductor manufacturing is the most complex engineering task humanity undertakes – and the policymaking behind it must be just as precise.”

Source link

Ex-Harvard morgue manager who stole body parts gets 8 years in prison | Crime News

Judge sentences former Harvard Medical School morgue manager for stealing organs and various body parts for sale to others.

The former manager of the Harvard Medical School morgue has been sentenced to eight years in prison for the theft and sale of body parts, taken from cadavers that had been donated for medical research.

Cedric Lodge, who managed the morgue for more than two decades before being arrested in 2023, was given an eight-year sentence by a US District Judge in Pennsylvania on Tuesday.

Recommended Stories

list of 3 itemsend of list

“He caused deep emotional harm to an untold number of family members left to wonder about the mistreatment of their loved ones’ bodies,” prosecutors wrote in a court filing.

The 58-year-old Lodge pleaded guilty to transporting stolen goods across state lines in May, with prosecutors stating that he had taken heads, faces, brains, skin, and hands from cadavers in the morgue to his home in Goffstown, New Hampshire, before selling them to several individuals.

Lodge’s wife, Denise, was also sentenced to one year in prison for her role in facilitating the sale of the stolen organs and body parts to several individuals, including two people in Pennsylvania, who then mostly resold them.

Prosecutors asked District Judge Matthew Brann in Williamsport, Pennsylvania, to give Lodge 10 years in prison, the maximum sentence for the crime, which they said “shocks the conscience” and was carried out “for the amusement of the disturbing ‘oddities’ community”.

Patrick Casey, a lawyer for Lodge, asked the judge for leniency, while conceding “the harm his actions have inflicted on both the deceased persons whose bodies he callously degraded and their grieving families”.

Harvard Medical School has yet to comment on Lodge’s sentencing, but has previously called his actions “abhorrent and inconsistent with the standards and values that Harvard, our anatomical donors, and their loved ones expect and deserve”.

A US court ruled in October that Harvard Medical School could be sued by family members who had donated the bodies of loved ones for medical research. In that case, Chief Justice Scott L Kafker described the affair as a “macabre scheme spanning several years”.

FILE PHOTO: A general view of the Harvard Medical School in the Longwood Medical Area in Boston, Massachusetts, U.S., May 15, 2022. Picture taken with a drone. REUTERS/Brian Snyder/File Photo
Harvard Medical School in the Longwood Medical Area in Boston, Massachusetts, US, in 2022 [Brian Snyder/Reuters]

Source link